Erythropoietin (EPO)
Also known as: EPO, Epo, Erythropoietin, rHuEPO, rhEpo, Epoetin, Epoetin alfa, Recombinant human erythropoietin, NESP, Darbepoetin, Neuro EPO, HBSP (helix B surface peptide), ARA290, Carbamoylated EPO
Glycoprotein hormone / hematopoietic growth factor / cytokine
What it is
Erythropoietin (EPO) is the active ingredient in FDA-approved drugs used to treat anemia in people with kidney disease, cancer, or HIV. It works by signaling the bone marrow to produce more red blood cells. Prescription-only; banned in sport by WADA; misuse for endurance enhancement is well-documented.
The scientific side
Erythropoietin (EPO) is a 30,400-dalton N-linked glycoprotein hormone produced primarily by peritubular fibroblastic cells in the renal cortex in adults, and by hepatocytes in the fetus (PMID 12524467; PMID 10334664). EPO production is regulated at the transcriptional level by hypoxia-inducible factors (HIFs), predominantly HIF-2, which bind to the EPO gene enhancer under conditions of hypoxia or anemia (PMID 21078592; PMID 10334664). EPO binds to a cell-surface receptor (EPO-R) that dimerizes upon activation, stimulating JAK2 tyrosine kinase and downstream pathways including Ras/MAP kinase, PI3-K/Akt, and STAT transcription factors (PMID 12524467; PMID 10334664; PMID 15854305). The primary hematopoietic function is to rescue erythroid progenitor cells from apoptosis, thereby promoting survival, proliferation, and differentiation of erythrocytic progenitors and increasing red blood cell mass (PMID 12524467; PMID 21078592; PMID 26919118). Beyond erythropoiesis, EPO signals through a heterodimeric receptor complex (EPO-R/β-common receptor, CD131) in non-hematopoietic tissues including brain, heart, skeletal muscle, adipose tissue, kidney, and retina (PMID 34440909; PMID 16738535; PMID 41206499). Non-erythroid EPO activities include neuroprotection, cardioprotection, anti-apoptosis, anti-inflammation, antioxidant effects, angiogenesis, and metabolic regulation including lipolysis and glucose homeostasis (PMID 39996752; PMID 21782802; PMID 33831836; PMID 17943138). EPO also modulates the hypothalamic-pituitary axis, influencing POMC expression and ACTH secretion. Concentration-dependent effects have been reported: low-dose EPO may exert tissue-protective effects via EPOR-βCR pathways, while high-dose EPO may exacerbate inflammation.
Class: Glycoprotein hormone / hematopoietic growth factor / cytokine
Administration & storage
- Administration
- Subcutaneous injection — used in administration study of rEPO in humans (PMID: 37644676)Intramuscular injection (via fibrin gel) — used in rat hindlimb ischemia model (PMID: 23294128)Intranasal administration — discussed as a route for Neuro EPO to avoid hematological side effects (PMID: 22376076)Intravenous administration — referenced for high-dose EPO; noted that only low levels cross the blood-brain barrier via this route (PMID: 17482474)
- Storage
- No storage conditions for EPO are described in the reviewed abstracts. Manual verification with product monographs or manufacturer guidance is required.
- Cautions
- Hypertension is a common adverse effect of EPO therapy, occurring even in healthy subjects; mechanisms include imbalance of vascular tone favoring vasoconstriction via nitric oxide, endothelin, and sympathoadrenal pathways.,High-dose EPO treatment following renal transplantation was associated with increased risk of thrombosis in four clinical trials; nonerythropoietic EPO derivatives may reduce this risk.,High-dose EPO may exacerbate systemic inflammation and disrupt the blood-brain barrier in sepsis models; a concentration-dependent dual role has been reported.,EPO treatment in cancer patients may promote tumor cell proliferation or survival in tumors expressing EPO-R; use in oncology requires prior evaluation of EPO signaling in the specific cancer type (PMID: 17385400; PMID: 15322761).,Anti-EPO antibody formation and EPO-induced pure red cell aplasia (PRCA) have been reported, though at low incidence in dialysis populations (estimated 1.27/1000 patient-years; PMID: 16105053).,Use of rHuEPO and darbepoetin to enhance athletic performance is banned by sports-governing bodies; excessive erythrocytosis can increase thrombogenicity and risk of deep vein, coronary, and cerebral thromboses.,Sterile technique is essential for any injectable peptide preparation to prevent contamination.
Legal & regulatory status
Recombinant human EPO (rHuEPO) is described in the reviewed literature as approved for clinical use in treating anemia associated with chronic renal failure, AIDS (anemia due to zidovudine), nonmyeloid malignancies…
Use of rHuEPO and darbepoetin to enhance athletic performance is officially banned by most sports-governing bodies. WADA publishes technical documents (TD EPO) governing anti-doping testing procedures.
Not stated in reviewed literature — requires manual verification
What it's studied for
- Anemia of chronic kidney disease / renal failure Human observational
- rHuEPO is described as currently used to treat patients with anemias associated with chronic renal failure. NESP (darbepoetin) maintains hemoglobin levels as effectively as rHuEPO with less frequent dosing. PMID 12524467 Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med. 2003.
- Recombinant human EPO (rhEpo) is a mainstay in the treatment of anaemia, primarily in renal failure; half-life of circulating rhEpo is 4–8 hours, typically administered 2–3 times weekly. NESP has a longer half-life (24–26 h). PMID 12460230 Jelkmann W. The enigma of the metabolic fate of circulating EPO. Eur J Haematol. 2002.
- In US hemodialysis patients, greater average prior EPO dose was associated with greater risk of death; EPO resistance may be reflected by total cumulative EPO dose. PMID 16377397 Kaysen GA et al. Challenging the validity of the EPO index. Am J Kidney Dis. 2006.
- Incidence of inadequate EPO response was 16.7 per 1000 patient-years on EPO in dialysis patients. EPO-induced PRCA and EPO antibodies had low incidence (estimated 1.27/1000 patient-years). PMID 16105053 Kharagjitsingh AV et al. Incidence of rEPO hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int. 2005.
- Anemia in myelodysplastic syndromes (MDS) Human observational
- Response (Hb increase >15 g/L or eliminated transfusion requirements) observed in 22/66 (33%) evaluable MDS patients treated with EPO alone. Median response duration 15 months. Baseline serum EPO level was a significant predictor of response and overall survival. PMID 12068800 Wallvik J et al. Serum EPO levels correlate with survival and independently predict response to EPO treatment in MDS. Eur J Haematol. 2002.
- Anemia in cancer patients receiving chemotherapy Mixed
- EPO can improve quality of life and recovery from anemia post-chemotherapy and radiation. However, EPO therapy shortens survival in some cancers where antiapoptotic EPO effects predominate in malignant cells. PMID 17385400 Sulkowska M et al. To give or not to give recombinant EPO to anemia endangered cancer patients. Prague Med Rep. 2006.
- EPO and EPO receptors are expressed in cancer cells; concern exists that rHuEPO may promote tumor growth via cell proliferation or angiogenesis, but evidence is inconclusive. PMID 15322761 Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells. Oncologist. 2004.
- Anemia in acute renal failure (ARF) in critically ill patients Human observational
- Retrospective cohort study (n=187): EPO use was not associated with decreased transfusion requirements or renal recovery in propensity-adjusted analyses. 37% of critically ill ARF patients were treated with EPO. Authors conclude a randomized controlled trial is needed. PMID 16105053 Park J et al. Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. Am J Kidney Dis. 2005.
- Neuroprotection (stroke, brain ischemia, neurodegenerative disease) Mixed
- EPO and EPOR exist and function in the nervous system. Clinical effectiveness of recombinant human EPO in ischemic stroke has been reported. EPO ameliorates neuronal injury via neuroprotective, anti-apoptotic, anti-inflammatory, antioxidant, angiogenic, neurogenic and neurotrophic effects. PMID 15272145 Genc S et al. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci. 2004.
- EPO administration provides neural protection in animal models of brain ischemia and trauma. Only low levels of EPO appear to cross the blood-brain barrier when administered at high dose intravenously. Therapeutic potential shown promise in early clinical trial. PMID 17482474 Noguchi CT et al. Role of EPO in the brain. Crit Rev Oncol Hematol. 2007.
- CSF EPO levels were lower in ALS patients than in AD and controls (p<0.05). Patients with rapid disease progression had lower CSF EPO. Authors suggest impaired EPO-associated neuroprotective capacity in ALS. PMID 17368721 Brettschneider J et al. Cerebrospinal fluid EPO in ALS. Neurosci Lett. 2007.
- Intranasal low-sialic acid EPO (Neuro EPO) retains neuroprotective effects without stimulating EPOR in bone marrow, potentially avoiding hematological side effects. Similar neuroprotective effects observed as original rHuEPO in ischemia models. PMID 22376076 Lagarto Parra A, Garcia Rodriguez JC. Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment. CNS Agents Med Chem. 2012.
- Metabolic regulation (glucose metabolism, fat mass, obesity) Animal studies only
- EPO enhances lipolysis and inhibits lipogenic gene expression in white adipose tissue, brown adipose tissue, skeletal muscle, and liver via EPO-EPOR-RUNX1 axis. Non-erythroid EPOR agonist ARA290 improves diet-induced obesity and glucose tolerance in animal models. PMID 39996752 Yin W, Noguchi CT. The Role of Erythropoietin in Metabolic Regulation. Cells. 2025.
- EPO increases POMC production in hypothalamic neurons and modulates ACTH secretion in pituitary. EPO regulation of metabolism is attributed to response in fat and hypothalamus-pituitary axis, not dependent on hematopoietic activity. PMID 28629513 Dey S, Noguchi CT. Erythropoietin and Hypothalamic-Pituitary Axis. Vitam Horm. 2017.
- Renal ischemia/reperfusion injury and kidney transplantation Mixed
- Four clinical trials using high-dose EPO following renal transplantation did not show protective effect for short-term renal function and reported increased thrombosis risk. Nonerythropoietic EPO derivatives (carbamoylated EPO, ARA290) improved renal function in preclinical models without affecting erythropoiesis. PMID 23964738 van Rijt WG et al. Erythropoietin-mediated protection in kidney transplantation. Transplant Int. 2014.
- Sepsis-associated encephalopathy (SAE) and neuroinflammation Mixed
- Retrospective study of 150 septic patients: elevated serum EPO was an independent risk factor for delirium. In animal studies, high-dose EPO exacerbated systemic inflammation, disrupted the blood-brain barrier, and impaired cognition. Low-dose EPO or HBSP inhibited microglia M1 polarization, attenuated neuroinflammatio PMID 41406833 Hu P et al. Exploring the EPO/EPOR-βCR/TLR9 pathways in SAE. Int Immunopharmacol. 2026.
- Therapeutic neovascularization / peripheral artery disease Animal studies only
- In rat hindlimb ischemia model, G-CSF and EPO co-delivered from fibrin gel showed superior blood flow reperfusion and capillary density compared to other treatments. Local high-concentration EPO trafficked CXCR4+ cells via SDF-1 to enhance neovascularization. PMID 23294128 Chen F et al. Co-delivery of G-CSF and EPO released from fibrin gel for therapeutic neovascularization in rat hindlimb ischemia model. Microcirculation. 2013.
- Ocular disorders (diabetic retinopathy, retinopathy of prematurity, glaucoma, AMD, optic neuritis, retinal detachment) Mixed
- EPO and EPO receptors are present in retinal layers. Review discusses mechanisms and pathways of EPO contributing to therapeutic effects and clinical applications across multiple ocular disorders, including various modes of administration and formulations. PMID 27285322 Ding SLS et al. Revisiting the role of EPO for treatment of ocular disorders. Eye. 2016.
- Bone remodeling and endothelial transdifferentiation of mesenchymal stem cells (MSCs) Mixed
- EPO induces osteogenic and endothelial transdifferentiation of multipotent MSCs via EPO-R signaling, leading to bone remodeling and induction of angiogenesis. PMID 34440909 Tsiftsoglou AS. EPO as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of MSCs. Cells. 2021.
- Cardioprotection (epilepsy, SUDEP) Animal studies only
- Review describes high EPO-R expression in cardiac progenitor cells contributing to myocardial regeneration under EPO stimulation, and discusses antiapoptotic role of EPO/EPO-R in brain and heart under hypoxic conditions such as epilepsy. PMID 32072891 Auzmendi J et al. EPO and EPO-Receptor System as Potential Actionable Mechanism for Protection of Brain and Heart in Refractory Epilepsy and SUDEP. Curr Pharm Des. 2020.
- Anti-doping detection (distinguishing endogenous from recombinant EPO) Human observational
- DBS samples (capillary blood from 111 athletes and venous blood from volunteers) analyzed with SAR-PAGE/Western blot successfully detected micro-doses of rEPO, endogenous EPO, and EPO c.577del gene variant. PMID 37942506 Heiland CE et al. Dried blood spots for EPO analysis. Drug Test Anal. 2024.
- De-N-glycosylated EPO detection by SDS-PAGE proposed as complementary confirmation method for rEPO in blood samples, capable of discriminating rEPO from VAR-EPO (c.577del variant) without false positives or false negatives. PMID 35603456 He S et al. Detection of de-N-glycosylated EPO with SDS-PAGE. Drug Test Anal. 2022.
Safety signals
- Hypertension: EPO elevates arterial blood pressure even in healthy subjects; mechanisms include vasoconstriction via nitric oxide dysregulation, endothelin, prostanoids, and sympathoadrenal/renin-angiotensin pathway activation. PMID 29228345
- Thrombosis: High-dose EPO treatment following renal transplantation associated with increased thrombosis risk in four clinical trials. PMID 23964738
- Pure red cell aplasia (PRCA) due to anti-EPO antibody formation: Reported in dialysis patients with estimated incidence of 1.27/1000 patient-years; 57 patients showed inadequate EPO response in cohort of 1677 ESRD patients. PMID 16105053
- EPO hyporesponse/resistance: Up to 10% of patients receiving EPO are hyporesponsive, requiring large doses; driven by inflammation, iron deficiency, hepcidin dysregulation, and EPO receptor disruption. PMID 18094727
- Potential tumor growth promotion: EPO and EPO-R expressed in cancer cells; antiapoptotic EPO signaling may promote proliferation and survival of cancer cells expressing EPO-R, and EPO therapy has been shown to shorten survival in some cancers. PMID 17385400
- Exacerbation of inflammation at high doses in sepsis-associated encephalopathy: High-dose EPO correlated with severity of sepsis and SAE, disrupted blood-brain barrier, and impaired cognition in animal models. PMID 41406833
- Thrombogenicity in athletes: Excessive erythrocytosis from EPO misuse can increase thrombogenicity and cause deep vein, coronary, and cerebral thromboses. PMID 12524467
- Reduced glomerular filtration rate: EPO decreases renal proximal tubular reabsorption, activating tubuloglomerular feedback mechanism and reducing GFR in healthy humans. PMID 20807784
- Suppression of endogenous EPO production: EPO treatment may suppress endogenous EPO production through decreased intrarenal oxygen consumption. PMID 20807784
- Greater average prior EPO dose associated with increased risk of death in hemodialysis patients in observational analysis. PMID 16377397
Contraindications
- Caution in cancer patients where EPO-R-expressing tumors are present, as EPO may promote tumor cell proliferation and survival; use requires prior investigation of EPO signaling in the specific cancer type before administration for anemia. PMID 17385400
- High-dose EPO should be used with caution or avoided in renal transplantation given four clinical trials showing no protective benefit and increased thrombosis risk. PMID 23964738
- EPO use for athletic performance enhancement is banned by sports-governing bodies due to thrombogenicity risk from excessive erythrocytosis. PMID 12524467
- Patients with a history of anti-EPO antibody formation or pure red cell aplasia (PRCA) represent a population requiring careful assessment before EPO re-administration. PMID 16105053
Protocol
Erythropoietin (EPO) is an approved clinical compound used medically, not as a research peptide. For medical use, see a doctor.
All studies (37)
- PMID 12068800 Human observational
Anemia in myelodysplastic syndromes (MDS) - PMID 12460230 Human observational
Anemia of chronic kidney disease / renal failure - PMID 12524467 Human observational
Anemia of chronic kidney disease / renal failure - PMID 16105053 Human observational
Anemia of chronic kidney disease / renal failure - PMID 16377397 Human observational
Anemia of chronic kidney disease / renal failure - PMID 35603456 Human observational
Anti-doping detection (distinguishing endogenous from recombinant EPO) - PMID 37942506 Human observational
Anti-doping detection (distinguishing endogenous from recombinant EPO) - PMID 15272145 Mixed
Neuroprotection (stroke, brain ischemia, neurodegenerative disease) - PMID 15322761 Mixed
Anemia in cancer patients receiving chemotherapy - PMID 17368721 Mixed
Neuroprotection (stroke, brain ischemia, neurodegenerative disease) - PMID 17385400 Mixed
Anemia in cancer patients receiving chemotherapy - PMID 17482474 Mixed
Neuroprotection (stroke, brain ischemia, neurodegenerative disease) - PMID 22376076 Mixed
Neuroprotection (stroke, brain ischemia, neurodegenerative disease) - PMID 23964738 Mixed
Renal ischemia/reperfusion injury and kidney transplantation - PMID 27285322 Mixed
Ocular disorders (diabetic retinopathy, retinopathy of prematurity, glaucoma, AMD, optic neuritis, r - PMID 34440909 Mixed
Bone remodeling and endothelial transdifferentiation of mesenchymal stem cells (MSCs) - PMID 41406833 Mixed
Sepsis-associated encephalopathy (SAE) and neuroinflammation - PMID 10334664
- PMID 15854305
- PMID 16738535
- PMID 17943138
- PMID 18094727
EPO hyporesponse/resistance: Up to 10% of patients receiving EPO are hyporesponsive, requiring large doses; driven by inflammation, iron deficiency, hepcidin dy - PMID 19595770
Not specified quantitatively in abstract; albumin-EPO fusion protein IALE reported as ~7.8-fold more potent than rHuEPO in increasing hematocrit of normal mice - PMID 20807784
Not stated quantitatively in abstract Not specified in abstract (human) - PMID 21078592
- PMID 21782802
- PMID 23294128 Animal studies only
Therapeutic neovascularization / peripheral artery disease - PMID 26919118
- PMID 28629513 Animal studies only
Metabolic regulation (glucose metabolism, fat mass, obesity) - PMID 29228345
Hypertension: EPO elevates arterial blood pressure even in healthy subjects; mechanisms include vasoconstriction via nitric oxide dysregulation, endothelin, pro - PMID 30807784
Not specified quantitatively in reviewed abstracts for healthy human studies Not specified in abstract (human) - PMID 32072891 Animal studies only
Cardioprotection (epilepsy, SUDEP) - PMID 32449841
- PMID 33831836
- PMID 37644676
50 IU/kg single dose Subcutaneous injection (human) - PMID 39996752 Animal studies only
Metabolic regulation (glucose metabolism, fat mass, obesity) - PMID 41206499